Advertisement
Advertisement
U.S. markets open in 2 hours 3 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Alterity Therapeutics Limited (ATHE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.2500-0.0300 (-2.34%)
At close: 4:00PM EDT
1.2700 +0.02 (+1.60%)
Pre-Market: 07:08AM EDT
Advertisement
Sign in to post a message.
  • N
    Nathan Siva
  • N
    N
    No interest. The big news didn’t even move the needle.
  • N
    N
    With every passing day, the chances of a start of Phase 2 for ATH434 in this quarter are diminishing. Only a matter of time before delay is announced.
  • N
    N
    News around the corner? Up pre-market. May be due to PBT2 chatter heating up?
  • F
    Farmer
    In looking at their poster on the long-waited natural progression study with Vanderbilt, they only reported region-of-interest QSM results. The QSM is a biomarker of iron accumulation. In nowhere they mentioned clinical endpoints. The QSM is at most a mechanistic endpoint. The intervention must show an effect on this endpoint. Otherwise all bets are off. Suppose that's the case, i.e. positive on QSM, FDA will still want to see efficacy on clinical endpoints (symptoms, et al. ....). They have a long way to go.
  • A
    Anna
    Buy buy buy!!!
  • R
    Russell
    Showing some life
  • p
    pete
    Nothing new here. Sorry for the new and old bag holders. Tuck it away or sell for the tax loss. Make no mistake this is dead money for the foreseeable future.
  • P
    Paul
    Mayo Clinic December 8th 2020 no specific test diagnose Parkinson's this may be the case for the slow enrollment do they want 100% confirmation just speculating
  • N
    N
    Is Stamler still alive? Haven’t heard from him in months.
  • j
    jac
    no news, no messages I am wondering what is the under line of this company?
  • N
    N
    1.56M volume and a spike to 1.39!! Any news? Rumor?
  • P
    Paul
    Better get going on Phase 2 I do not know disagreement on the parameters all I know is they're burning money cannot afford Phase 1 very impressive poor PR say the least
  • A
    Archimedes
    Alterity (ATHE) has huge upside potential. Accordingly, I am holding fast on my relatively large position. I don't really need overly frequent news updates to bolster my confidence in their science & technology... I absolutely love their innovative patented IP. GLTA!
    Bullish
  • B
    Barry
    Check out today's Endpoints News lead article about Eli Lilly's actions and plans in terms of their announced partnership with Lycia Therapeutics. Perhaps they and Lyrica's CEO are familiar with ATHE and their small molecule drugs seeing as Dr. Sinclair's US office is in San Francisco too. It sure would be fantastic if their clinical ( & secret) targets to evaluate included ATHE 434 & PBT2 among others. No worries, Dr. Sinclair is on the case and all over this great opportunity!?
    Bullish
  • N
    N
    Why is this s#*& rolling downhill today?
  • e
    ed
    ATHE will start seeing more buy ratings in the coming months
  • e
    ed
    looks like ATHE is on the rebound. $2. seems realistic by start of phase 2 given the $4. price target. 45% in potential gains to that point. NOW is the time to pull the trigger.
    Bullish
Advertisement
Advertisement